MedTrace Logo

Prognostic Value of CD64 Marker for Patients in Intensive Care Unit

NCT03617796 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2018-08-06

No results posted yet for this study

Summary

Among patients admitted to the intensive care unit (ICU), early recognition of those with the highest risk of death is of paramount importance. Since clinical judgment is sometimes uncertain biomarkers could provide additional information likely to guide critical illness management. We want to evaluate the prognostic value of leucocyte surface expression of CD64.

Blood samples for CD64 biomarker measurement will be obtained daily during the patient's hospitalization. The primary outcome was all-cause death at D28 after admission

Conditions

  • Systemic Inflammatory Response Syndrome
  • Intensive Care

Sponsors & Collaborators

  • Central Hospital, Nancy, France

    lead OTHER

Principal Investigators

  • El Mehdi SIAGHY, Mr · CHRU de NANCY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-09-10
Primary Completion
2018-12-09
Completion
2018-12-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03617796 on ClinicalTrials.gov